leisure time -WSS

leisure time

author：knowledge 2025-09-30 00:35:02 - browse：5173

Jeremey Wyatt ActiGraph

As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Biden declares emergency in flood

WSS

Food makers to regulators: Ultra

Create a giant ice tray with this foil pan hack to keep food cold this summer

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Medicare wants to send $9 billion to 340B hospitals

Recent heat wave in the Mediterranean caused by climate change: Study

Will the IRA bring competition to the biologics market?

Wikipedia

leisure time

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

PEPFAR is under serious threat — and so is global health

Apple is now the first public company to be valued at $3 trillion

FDA approves updated Covid vaccines

Walensky prepares to leave CDC — and Congress — behind

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

BioMarin wins approval for gene therapy to treat hemophilia A

WATCH: Why do bright lights make us see spots?

BioMarin wins approval for gene therapy to treat hemophilia A

WATCH: Why do bright lights make us see spots?

hotspot

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

How to make the FDA’s new prescription one

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

New weight loss drugs vying to be the next Wegovy or Mounjaro

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Food makers to regulators: Ultra

focus

explore

Wikipedia

Wikipedia